In this context, reports showing that CMV-driven expansion of NKG2C+CD57+ NK cells in HSCT patients correlated with reduced leukemia relapse rates, in addition to the advantage of their longevity, raised the possibility of an immunotherapeutic role for adaptive NKG2C+ NK cells against leukemia. This evidence concerns the gene KLRC2 and leukemia.